论文部分内容阅读
目的:探讨门冬胰岛素30与口服降糖药治疗2型糖尿病的经济效果。方法:采用回顾性研究方法,选择165例2型糖尿病患者,随机分为3组(A组:门冬胰岛素30;B组:二甲双胍肠溶胶囊+格列美脲片+阿卡波糖片;C组:二甲双胍片+格列美脲片+瑞格列奈片)进行评价。结果:A、B、C 3组成本分别为140.80,141.82,251.72元,总有效率分别为87.93%,79.25%,83.33%(P>0.05),成本-效果比分别为1.60,1.79,3.02。结论:A组优于B和C组。
Objective: To investigate the economic effect of insulin aspart 30 and oral hypoglycemic agents on type 2 diabetes mellitus. Methods: A retrospective study was conducted to select 165 patients with type 2 diabetes mellitus who were randomly divided into 3 groups (group A: insulin aspart 30; group B: metformin enteric capsules + glimepiride tablets + acarbose tablets; Group C: metformin tablets + glimepiride tablets + repaglinide tablets) were evaluated. Results: The costs of A, B and C 3 groups were 140.80, 141.82 and 251.72 yuan, respectively. The total effective rates were 87.93%, 79.25% and 83.33%, respectively. The cost-effectiveness ratios were 1.60, 1.79 and 3.02 respectively. Conclusion: A group is better than B and C group.